Despite the availability of licensed Ebola vaccines that have helped control outbreaks, researchers continue to pursue new vaccine platforms that may improve safety, manufacturing flexibility, and the breadth of immune protection. One such candidate, known as iEvac-Z, is an inactivated whole-virus vaccine designed to expose the immune system to multiple Ebola antigens while eliminating the risk of viral replication.

The vaccine is based on a genetically modified Ebola virus lacking the VP30 gene, a critical component required for viral replication. Because the modified virus can only grow in specialized laboratory cells, it can be produced under biosafety level 2 conditions. Researchers subsequently inactivate the virus using β-propiolactone, preserving key viral proteins while rendering the vaccine noninfectious.

Prior preclinical studies demonstrated that iEvac-Z protected nonhuman primates from a lethal Ebola challenge. Building on those findings, investigators conducted an open-label, dose-escalation Phase 1 trial involving 29 healthy Japanese men between 20 and 45 years of age. Participants received either a low-dose or high-dose formulation administered intramuscularly in two injections spaced four weeks apart and were monitored for one year.

Safety Profile

The vaccine was generally well tolerated across both dose groups. Most reported adverse events were mild and consisted primarily of reactions at the injection site. Overall rates of adverse events were comparable between the low- and high-dose cohorts.

One participant in the high-dose group experienced significant redness at the injection site after the first dose and did not receive the second vaccination. Investigators noted that this individual had unusually high preexisting Ebola glycoprotein antibody levels before enrollment.

No major safety signals emerged during the study, providing preliminary reassurance regarding the vaccine’s tolerability.

Strong Antibody Responses Observed

By eight weeks after vaccination, all evaluable participants developed Ebola glycoprotein-specific IgG antibodies, achieving a 100% seroconversion rate. Antibody levels increased in a dose-dependent manner, with recipients of the higher dose generating substantially stronger responses than those receiving the lower dose.

Neutralizing antibodies, which play an important role in preventing viral infection, were also detected more frequently among participants in the high-dose group than in the low-dose cohort.

Importantly, the vaccine stimulated immune responses against multiple Ebola proteins, including glycoprotein, nucleoprotein, and VP40. This broader antigenic coverage sets iEvac-Z apart from vaccines that target a single viral protein and could potentially contribute to more comprehensive immune protection.

Researchers also observed durability of the immune response. More than one-third of participants receiving the higher dose maintained detectable glycoprotein-specific antibodies one year after vaccination, suggesting the potential for lasting immunologic memory.

Balanced Immune Activation

Analysis of cytokine responses following immunization indicated relatively modest immune activation overall. The greatest increase was observed in RANTES, an immune-signaling molecule associated with T-cell recruitment and inflammatory responses. Researchers noted that the cytokine profile appeared balanced and did not indicate excessive immune stimulation.

Next Steps for Development

The investigators acknowledged several limitations, including the small sample size, enrollment of only male participants, and the absence of T-cell response measurements. Nevertheless, the findings provide initial clinical evidence supporting the inactivated EBOVΔVP30 vaccine platform.

According to the researchers, the combination of a favorable safety profile, production advantages under lower biosafety requirements, and the ability to induce antibodies against multiple Ebola antigens warrants continued development of the candidate. Future studies are expected to evaluate adjuvanted formulations aimed at strengthening neutralizing antibody responses while preserving safety.

If confirmed in larger and more diverse populations, iEvac-Z could represent a promising addition to the arsenal of vaccines available for combating future Ebola outbreaks.